The QIV was associated with reduced risks of a body temperature above @C and lower respiratory tract illness , as compared with the control vaccine , in the per-protocol cohort ( relative risk , @ -LSB- @ % CI , @ to @ -RSB- and @ -LSB- @ % CI , @ to @ -RSB- , respectively ) .